Novel INXN-4001 Triple Effector Plasmid in Heart Failure

Inclusion Criteria:

Male and female adult patients with a stable LVAD implanted for end-stage heart failure
Must be managed in an outpatient setting and on stable medication regimen

Exclusion Criteria:

Women who are pregnant or nursing
Patients who have been on another clinical trial for heart failure in the last 90 days, or have received any stem cell or gene therapy within the previous year.
Patient is not able to complete a Six Minute Walk Test or unable to tolerate an LVAD wean in the past 3 months
Patient has an active infection requiring systemic antibiotics or an autoimmune disease requiring systemic immunosuppressants
Patient has a history of arrhythmia, uncontrolled diabetes, diabetic retinopathy, systemic lupus erythematosus, macular degeneration, hyper-coagulation, or stroke
Patient has had a myocardial infarction related to ischemia within the past 30 days
Patient has had certain prior surgeries such as organ transplant, cardiac transplantation, left ventricle reduction surgery, or cardiomyoplasty
Patient has infectious disease, such as hepatitis B or C, or human immunodeficiency virus (HIV)
Patient has a history of cancer within the past 3 years